Yağcı-Küpeli Begül, Özkan Ayşe
Department of Pediatric Hematology/Oncology, University of Health Sciences, Adana City Training and Research Hospital, Adana, Turkey.
Pediatr Hematol Oncol. 2020 Nov;37(8):707-716. doi: 10.1080/08880018.2020.1795328. Epub 2020 Jul 24.
Cure rates of childhood cancer need to be improved in low-income countries and vulnerable populations such as refugees. We aimed to compare the outcome and associated factors in Syrian refugee and Turkish children with cancer treated at our hospital.Files of patients were reviewed for age, tumor type, stage, treatment, compliance to treatment, relapse or progression status, outcomes, secondary malignancy (SM) and treatment-related mortality (TRM). Overall (OS) and event-free survival rates (EFS) were analyzed.105 refugees and 304 Turkish children were treated between January 2012 and January 2019. Median age and median follow-up time were significantly lower in the Syrian group (p=0.046, p<0.001, respectively). Metastatic or advanced-stage disease was significantly more frequent in refugees (p=0.002). Relapse or progression and poor compliance to treatment were more common in refugees (p=0.01, p<0.001, respectively). Rates of OS were 55.7% and 69.7%, EFS were 28.9% and 55.7% in Syrian and Turkish patients. OS and EFS were lower in refugees compared to Turkish patients (p=0.01, p<0.001, respectively). EFS was significantly lower in refugees with poor compliance to treatment (p<0.001). TRM was reported in 12 (8 Syrian, 4 Turkish) patients. SM was detected in 3 (2 Turkish, 1 Syrian) children.Inferior survival rates were detected in Syrian refugee children compared to Turkish children. Besides from cancer-specific factors such as stage and tumor type, a series of barriers in accessing cancer care resulting in poor compliance to treatment might have been responsible from lower survival rates in Syrian children.
低收入国家以及难民等弱势群体的儿童癌症治愈率有待提高。我们旨在比较在我院接受治疗的叙利亚难民儿童和土耳其患癌儿童的治疗结果及相关因素。回顾患者档案,了解其年龄、肿瘤类型、分期、治疗情况、治疗依从性、复发或进展状态、治疗结果、继发性恶性肿瘤(SM)以及治疗相关死亡率(TRM)。分析总生存率(OS)和无事件生存率(EFS)。
2012年1月至2019年1月期间,共治疗了105名难民儿童和304名土耳其儿童。叙利亚组的中位年龄和中位随访时间显著更低(分别为p = 0.046,p < 0.001)。难民中转移性或晚期疾病更为常见(p = 0.002)。复发或进展以及治疗依从性差在难民中更为普遍(分别为p = 0.01,p < 0.001)。叙利亚和土耳其患者的OS率分别为55.7%和69.7%,EFS率分别为28.9%和55.7%。与土耳其患者相比,难民的OS和EFS更低(分别为p = 0.01,p < 0.001)。治疗依从性差的难民的EFS显著更低(p < 0.001)。12名患者报告了TRM(8名叙利亚患者,4名土耳其患者)。3名儿童(2名土耳其儿童,1名叙利亚儿童)检测到SM。
与土耳其儿童相比,叙利亚难民儿童的生存率较低。除了分期和肿瘤类型等癌症特异性因素外,一系列获得癌症治疗的障碍导致治疗依从性差,这可能是叙利亚儿童生存率较低的原因。